|Bid||6.00 x 3100|
|Ask||6.78 x 3000|
|Day's Range||5.95 - 6.28|
|52 Week Range||2.71 - 10.89|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||7.94|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.70|
Endo International plc (NASDAQ: ENDP) will announce its first-quarter 2021 financial results on May 6, 2021 and members of its senior management team will host a conference call and webcast on May 7, 2021 at 7:30am ET before the U.S. financial markets open.
Endo International plc (NASDAQ: ENDP) today announced that Phase 3 data evaluating Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women was published in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery. In addition to Phase 3 studies, the publication also includes a supplemental video that demonstrates the injection techniques for QWO.
Endo International plc (NASDAQ: ENDP) and ADVANZ PHARMA Corp. Limited, a specialty pharmaceutical company with a strategic focus on complex medicines, are pleased to announce today that Endo International plc's subsidiary Endo Ventures Limited has entered into a definitive agreement with Correvio International Sàrl entity, a subsidiary of ADVANZ PHARMA, to commercialize and distribute on an exclusive basis Xydalba® (dalbavancin hydrochloride) in Canada.